Navigation Links
Actinium Pharmaceuticals, Inc. Receives $3.5m from Exercise of Warrants
Date:6/7/2013

NEW YORK, June 7,­­­­ 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM) announced today the recent issuance of 2,095,204 of its shares of common stock pursuant to the exercise of A-Warrants originally issued in connection with a private placement that closed in January 2013.  The warrants were exercised at US$ 1.65 per share, resulting in gross proceeds of US$ 3,457,087 for the Company.  As of June 7, 2013 the total number of outstanding common stock is 15,825,394 shares.

"The proceeds from these exercised warrants will be used for the Companies clinical and preclinical programs and for general working capital," said Sergio Traversa, Interim Chief Executive Officer of Actinium Pharmaceuticals.  "This capital will allow us to continue to develop our drug candidates for treatment of the most difficult forms of cancer, including Acute Myeloid Leukemia, where they have made significant advances and already helped a number of patients," added Dragan Cicic, MD, Chief Medical Officer of Actinium Pharmaceuticals.  "The Company intends to advance its programs into late phases of clinical trials and add new programs by the end of 2013."

Shareholders exercised 2,095,204 (67.2%) of the 3,118,988 originally issued A-warrants. 

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc., based in New York, NY, is a biopharmaceutical company that develops innovative alpha particle immunotherapeutics based on its proprietary platform for the therapeutic utilization of alpha particle emitting actinium-225 and bismuth-213 radiopharmaceuticals in association with monoclonal antibodies.

For more information:

Visit our web site www.actiniumpharmaceuticals.com or

Contact:
Segio Traversa, CEO
Actinium Pharmaceuticals Inc.
E-mail: straversa@actiniumpharmaceuticals.com


Media:
Dennis S. Dobson Jr.
Tel: (203) 258-0150
E-mail: dsdobson@optonline.com
www.dobsonmediagroup.com

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance.  No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.


'/>"/>
SOURCE Actinium Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Actinium Pharmaceuticals Clinical Results to be Presented at 8th International Symposium on Targeted Alpha Therapy Conference
2. Actinium Pharmaceuticals, Inc. Receives Notice of Patent Allowance for a Key Application
3. Cactus Ventures, Inc. Changes Name to Actinium Pharmaceuticals, Inc.
4. Actinium Pharmaceuticals, Inc. To Present at the 15th Annual BIO CEO Investor Conference
5. Actinium Pharmaceuticals to Present at EMIT Targeted Radiotherapy Conference
6. University of Pennsylvania joins Actinium Pharmaceuticals Multicenter Actimab-A Trial
7. Additional Clinical Data from Two Trials on Actinium Pharmaceuticals Iomab-B to be Presented at American Society of Hematology (ASH) Annual Meeting
8. Actinium Pharmaceuticals Sponsors Webinar on Clinical Use of Alpha Immunotherapy
9. Actinium Pharmaceuticals Announces New Round of Financing
10. Gerri Henwood Joins Actinium Pharmaceuticals as Chief Development Officer
11. Actinium Pharmaceuticals Commences Screening for the Second Cohort of Patients in the Companys Ongoing Phase I/II Trial in Acute Myeloid Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... PROVIDENCE, R.I. , Sept. 25, 2017 /PRNewswire/ ... immunogenicity assessment, vaccine design, and immune-engineering today announced ... focused on the development of personalized therapeutic cancer ... and has provided exclusive access to enabling technologies ... MSc Eng., MBA will lead EpiVax Oncology as ...
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., a ... today announced that it has been ranked #1 by its ... Book™ Rankings 2017 User Survey. ZirMed was recognized as ... large hospitals and medical centers over 200 beds and holds ... healthcare technology user survey history. ...
(Date:9/12/2017)... LAKES, N.J. , Sept. 12, 2017  Consumer reviews on ... Embrace Hearing as the number one company for hearing aids, ... ReSound™ and fifteen other brands. ... Embrace Hearing Named #1 by Consumers For Hearing Aids ... Embrace Hearing is an online store that provides ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... As health professionals work to improve their ... The patient is doing more than filling out a survey; in many cases health ... increasing emphasis in health care and research on the importance of active engagement with ...
(Date:10/13/2017)... , ... October 13, 2017 ... ... of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ... on guideline updates for the primary prevention of cardiovascular diseases during the ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for professional ... action towards gender equality at their inaugural Summit in New York City in June. ... a social audience of over 3 million. To watch the Mobilize Women video, ...
(Date:10/13/2017)... ... 2017 , ... “The Journey: From the Mountains to the Mission Field”: the ... in the Philippines. “The Journey: From the Mountains to the Mission Field” is the ... She has taught all ages and currently teaches a class of ladies at her ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
Breaking Medicine News(10 mins):